Table 5.
Distribution of C4 polymorphisms in Graves' disease patients with or without vitiligo
| Variations | Vitiligo |
P value, individuala [OR (95%CI), individual]c |
P value b | OR (95%CI)d | |
|---|---|---|---|---|---|
| No, N (%) | Yes, N (%) | ||||
| C4 CNV | |||||
| 4 | 258 (50.6) | 56 (49.1) | 0.836 | 0.002 | (Reference) |
| < 4 | 97 (19.0) | 37 (32.5) | 0.002 [1.297 (0.434-3.874)] | 1.334 (0.415-4.289) | |
| > 4 | 155 (30.4) | 21 (18.4) | 0.011 [0.987 (0.362-2.691)] | 1.076 (0.370-3.133) | |
| C4A CNV | |||||
| 2 | 330 (64.7) | 65 (57.0) | 0.133 | (Reference) | |
| < 2 | 52 (10.2) | 27 (23.7) | 2.650 × 10-4 [5.153 (1.629-16.3000] | 0.001 | 5.579 (1.659-18.763) |
| > 2 | 128 (25.1) | 22 (19.3) | 0.225 | 1.289 (0.414-4.013) | |
| C4B CNV | |||||
| 2 | 310 (60.8) | 67 (58.8) | 0.751 | (Reference) | |
| < 2 | 112 (22.0) | 31 (27.2) | 0.267 | 0.414 | 1.133 (0.355-3.614) |
| > 2 | 88 (17.3) | 16 (14.0) | 0.487 | 2.107 (0.687-6.467) | |
| C4 polymorphisms | |||||
| A2B2 | 213 (41.8) | 41 (36.0) | 0.292 | 0.03 | (Reference) |
| A2B1 | 62 (12.2) | 16 (14.0) | 0.638 | 0.889 (0.175-4.524) | |
| A3B2 | 57 (11.2) | 7 (6.1) | 0.125 | 0.756 (0.132-4.335) | |
| A2B3 | 40 (7.8) | 4 (3.5) | 0.154 | 1.111 (0.151-8.205) | |
| A3B1 | 25 (4.9) | 7 (6.1) | 0.638 | 1.484 (0.199-11.089) | |
| A1B2 | 22 (4.3) | 12 (10.5) | 0.019 [2.035(0.335-12.368)] | 2.745 (0.384-19.599) | |
| Other | 91 (17.8) | 27 (23.7) | 3.471 (1.046-11.525) | ||
Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
aIndividual C4 CNVs and polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 2 × 2 contingency tables.
b CNV of C4, C4A and C4B between GD patients with or without vitiligo were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.
dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.